Hansoh Pharmaceutical Group Company Limited
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People's Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products … Read more
Hansoh Pharmaceutical Group Company Limited (HNSPF) - Total Assets
Latest total assets as of June 2025: $35.07 Billion USD
Based on the latest financial reports, Hansoh Pharmaceutical Group Company Limited (HNSPF) holds total assets worth $35.07 Billion USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Hansoh Pharmaceutical Group Company Limited - Total Assets Trend (2020–2024)
This chart illustrates how Hansoh Pharmaceutical Group Company Limited’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Hansoh Pharmaceutical Group Company Limited - Asset Composition Analysis
Current Asset Composition (December 2024)
Hansoh Pharmaceutical Group Company Limited's total assets of $35.07 Billion consist of 86.7% current assets and 13.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 71.5% |
| Accounts Receivable | $3.13 Billion | 9.9% |
| Inventory | $651.22 Million | 2.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $245.29 Million | 0.8% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2024)
This chart illustrates how Hansoh Pharmaceutical Group Company Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hansoh Pharmaceutical Group Company Limited's current assets represent 86.7% of total assets in 2024, an increase from 83.1% in 2020.
- Cash Position: Cash and equivalents constituted 71.5% of total assets in 2024, up from 20.6% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is accounts receivable at 9.9% of total assets.
Hansoh Pharmaceutical Group Company Limited Competitors by Total Assets
Key competitors of Hansoh Pharmaceutical Group Company Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Hansoh Pharmaceutical Group Company Limited - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Hansoh Pharmaceutical Group Company Limited generates 0.39x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Hansoh Pharmaceutical Group Company Limited generates $ 13.81 in net profit.
Hansoh Pharmaceutical Group Company Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.56 | 7.98 | 9.86 |
| Quick Ratio | 8.38 | 7.81 | 9.69 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $27.22 Billion | $ 23.97 Billion | $ 23.21 Billion |
Hansoh Pharmaceutical Group Company Limited - Advanced Valuation Insights
This section examines the relationship between Hansoh Pharmaceutical Group Company Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.89 |
| Latest Market Cap to Assets Ratio | 0.10 |
| Asset Growth Rate (YoY) | -4.2% |
| Total Assets | $31.66 Billion |
| Market Capitalization | $3.25 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Hansoh Pharmaceutical Group Company Limited's assets below their book value (0.10 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Hansoh Pharmaceutical Group Company Limited's assets decreased by 4.2% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Hansoh Pharmaceutical Group Company Limited (2020–2024)
The table below shows the annual total assets of Hansoh Pharmaceutical Group Company Limited from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $31.66 Billion | -4.18% |
| 2023-12-31 | $33.04 Billion | +10.12% |
| 2022-12-31 | $30.00 Billion | +10.46% |
| 2021-12-31 | $27.16 Billion | +30.63% |
| 2020-12-31 | $20.79 Billion | -- |